5/4/2020 6:35:19 AM
Epizyme Q1 Loss Per Share $0.51 Vs Loss $0.59 Last Year
2/24/2020 6:36:41 AM
Epizyme Q4 Net Loss Attributable To Common Stockholders $56.4 Mln Or $0.59/Shr Vs $22.9 Mln Or $0.29/Shr Last Year
2/14/2020 6:38:07 AM
Epizyme Says FDA Accepted For Filing NDA For Accelerated Approval Of TAZVERIK
1/23/2020 5:20:13 PM
Epizyme Says FDA Granted Accelerated Approval Of TAZVERIK
1/6/2020 6:33:00 AM
Epizyme Exercises Option To Sell $50 Mln Of Common Stock To Royalty Pharma; Highlights Key 2020 Initiatives
12/18/2019 7:11:43 AM
Epizyme Says Trading Of Stock Has Been Halted; Oncology Drug Advisory Committee To Review Tazemetostat Today
11/5/2019 8:14:56 AM
Royalty Pharma To Purchase Future Royalties On Tazemetostat From Eisai For $330 Mln
11/4/2019 7:11:45 AM
Epizyme Announces Funding Agreements With Royalty Pharma And Its Affiliate Pharmakon Advisors
9/4/2019 6:34:10 AM
Epizyme Appoints Grant Bogle And Victoria Richon To Board
8/9/2019 6:32:50 AM
Epizyme Q2 Net Loss Attributable To Common Stockholders $48.5 Mln Or $0.53/Shr Vs $29.1 Mln Or $0.42/Shr Last Year
7/25/2019 6:42:10 AM
Epizyme Announces FDA Filing Acceptance Of NDA And Priority Review For Tazemetostat For Epithelioid Sarcoma
6/12/2019 3:58:31 PM
Wedbush Reiterates Epizyme, Inc. (EPZM) At Outperform With $21 Price Target
6/3/2019 6:35:41 AM
Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat For Epithelioid Sarcoma At 2019 ASCO Annual Meeting
5/30/2019 6:35:01 AM
Epizyme Submits NDA To FDA For Tazemetostat For Epithelioid Sarcoma Treatment